Northwest Biotherapeutics (NWBO) 4.88 $NWBO
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Northwest Biotherapeutics, Inc. and Lead Plaintiff Deadline October 26, 2015
ACCESSWIRE - Fri Oct 23, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 23, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Maryland on behalf of those who purchased securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NasdaqCM: NWBO), during the period between March 8, 2013 and August 20, 2015 inclusive. (the "Class Period" .
NWBO: 4.88 (+0.01)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO
GlobeNewswire - Thu Oct 22, 9:43PM CDT
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period" . The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws.
NWBO: 4.88 (+0.01)
Northwest Bio Bothers British Bestie for Bounteous Bucks
at The Street - Thu Oct 22, 11:18AM CDT
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
NWBO: 4.88 (+0.01), KITE: 68.05 (-0.72), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), FPRX: 32.15 (+0.27)
NW Bio Has Entered Into An Agreement For $30 Million Of New Equity Funding From Woodford Investment Management
PR Newswire - Wed Oct 21, 11:00AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has entered into agreement for funding of $30 million from Woodford Investment Management in the UK ("Woodford" .
NWBO: 4.88 (+0.01)
NW Bio Issues Statement on Highly Unusual Trading Activity
PR Newswire - Mon Oct 19, 9:01AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the recent highly unusual trading activity in the Company's stock:
NWBO: 4.88 (+0.01)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Northwest Biotherapeutics, Inc. Of Upcoming Deadline
Business Wire - Thu Oct 15, 5:45PM CDT
Rigrodsky & Long, P.A.:
NWBO: 4.88 (+0.01)
Harwood Feffer LLP Announces Investigation of Northwest Biotherapeutics, Inc.
PR Newswire - Wed Oct 14, 3:40PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Northwest Biotherapeutics, Inc. ("Northwest" or the "Company" (NASDAQ: NWBO), concerning whether the board has breached its fiduciary duties to shareholders.
NWBO: 4.88 (+0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Northwest Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NWBO
GlobeNewswire - Mon Oct 12, 7:03AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ:NWBO) and certain of its officers. The class action, filed in United States District Court, District of Maryland, Greenbelt Division, and docketed under 8:15-cv-02532, is on behalf of a class consisting of all persons or entities who purchased Northwest Biotherapeutics securities between March 8, 2013 and August 20, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
NWBO: 4.88 (+0.01)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Northwest Biotherapeutics, Inc.
PR Newswire - Wed Sep 23, 5:08PM CDT
Rigrodsky & Long, P.A.:
NWBO: 4.88 (+0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Biotherapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NWBO
GlobeNewswire - Wed Sep 23, 2:31PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (Nasdaq:NWBO) ("Northwest Biotherapeutics" or the "Company" securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff.
NWBO: 4.88 (+0.01)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.33 (-0.13), NWBO: 4.88 (+0.01), MRK: 54.66 (-0.21), CLDX: 12.06 (-0.22), NLNK: 38.27 (+0.89), GALE: 1.68 (-0.05), GSK: 43.06 (+0.27), IMUC: 0.39 (-0.01), NVS: 90.43 (-0.53)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Northwest Biotherapeutics, Inc.
PR Newswire - Fri Sep 18, 6:45PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NASDAQ: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" .
NWBO: 4.88 (+0.01)
Northwest Bio CEO: Brain Tumor Vaccine Study Still Suspended
at The Street - Wed Sep 16, 1:24PM CDT
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
NWBO: 4.88 (+0.01)
NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015
PR Newswire - Wed Sep 16, 8:20AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015.
NWBO: 4.88 (+0.01)
Deadline in Lawsuit for Investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Sep 15, 9:40AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in Maryland on behalf of certain purchasers of shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged Securities Laws Violations by Northwest Biotherapeutics, Inc.
NWBO: 4.88 (+0.01)
NW to Present at 4th Annual SMi Cancer Vaccines Conference in London On Wednesday, September 16, 2015
PR Newswire - Mon Sep 14, 8:51AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that CEO Linda Powers will present at the SMi 4th Annual Cancer Vaccines Conference in London on Wednesday, September 16, 2015 at the Marriott Hotel, Regents Park.
NWBO: 4.88 (+0.01)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Northwest Biotherapeutics, Inc. and Lead Plaintiff Deadline October 26, 2015
ACCESSWIRE - Fri Oct 23, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 23, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Maryland on behalf of those who purchased securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NasdaqCM: NWBO), during the period between March 8, 2013 and August 20, 2015 inclusive. (the "Class Period" . NWBO: 4.88 (+0.01)
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Northwest Biotherapeutics, Inc. - NWBO
GlobeNewswire - Thu Oct 22, 9:43PM CDT
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) securities from March 8, 2013 through August 20, 2015, all dates inclusive (the "Class Period"
. The lawsuit seeks to recover damages for Northwest Biotherapeutics, Inc. investors under the federal securities laws. NWBO: 4.88 (+0.01)
Northwest Bio Bothers British Bestie for Bounteous Bucks
at The Street - Thu Oct 22, 11:18AM CDT
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
NWBO: 4.88 (+0.01), KITE: 68.05 (-0.72), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), FPRX: 32.15 (+0.27)
NW Bio Has Entered Into An Agreement For $30 Million Of New Equity Funding From Woodford Investment Management
PR Newswire - Wed Oct 21, 11:00AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Company has entered into agreement for funding of $30 million from Woodford Investment Management in the UK ("Woodford" . NWBO: 4.88 (+0.01)
NW Bio Issues Statement on Highly Unusual Trading Activity
PR Newswire - Mon Oct 19, 9:01AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today issued the following statement addressing the recent highly unusual trading activity in the Company's stock: NWBO: 4.88 (+0.01)
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Northwest Biotherapeutics, Inc. Of Upcoming Deadline
Business Wire - Thu Oct 15, 5:45PM CDT
Rigrodsky & Long, P.A.:
NWBO: 4.88 (+0.01)
Harwood Feffer LLP Announces Investigation of Northwest Biotherapeutics, Inc.
PR Newswire - Wed Oct 14, 3:40PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Northwest Biotherapeutics, Inc. ("Northwest" or the "Company"
(NASDAQ: NWBO), concerning whether the board has breached its fiduciary duties to shareholders. NWBO: 4.88 (+0.01)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Northwest Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - NWBO
GlobeNewswire - Mon Oct 12, 7:03AM CDT
Pomerantz LLP announces that a class action lawsuit has been filed against Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ:NWBO) and certain of its officers. The class action, filed in United States District Court, District of Maryland, Greenbelt Division, and docketed under 8:15-cv-02532, is on behalf of a class consisting of all persons or entities who purchased Northwest Biotherapeutics securities between March 8, 2013 and August 20, 2015 inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" . NWBO: 4.88 (+0.01)
Global & USA Cancer Immunotherapy Market Analysis 2015 - Forecasts to 2020
PR Newswire Europe - Fri Oct 09, 7:10AM CDT
Research and Markets(http://www.researchandmarkets.com/research/lgcqzq/global_and_usa [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa]) has announced the addition of the "Global & USA Cancer Immunotherapy Market Analysis to 2020" [http://www.researchandmarkets.com/research/lgcqzq/global_and_usa] report to their offering.
HTBX: 3.93 (-0.14), BIIB: 290.51 (-3.21), NWBO: 4.88 (+0.01), CVM: 0.53 (-0.01), CLDX: 12.06 (-0.22), MACK: 9.34 (-0.22), INO: 6.33 (-0.13), NLNK: 38.27 (+0.89), JUNO: 51.76 (+0.37), GALE: 1.68 (-0.05), IMMU: 2.99 (+0.08), ADXS: 11.09 (-0.66), ADRO: 27.01 (+0.11), IMGN: 11.70 (+0.16), AMGN: 158.18 (-2.40), SPPI: 5.21 (+0.10), LLY: 81.57 (-0.43), BMY: 65.95 (-1.36), GSK: 43.06 (+0.27), SRNE: 8.64 (-0.26), ONTY: 2.96 (-0.02), IMUC: 0.39 (-0.01), PGNX: 7.34 (-0.12), ARGS: 5.06 (-0.05), GBIM: 2.48 (-0.09), BLCM: 12.51 (-0.50), SGEN: 41.49 (-0.65), KITE: 68.05 (-0.72), MRK: 54.66 (-0.21)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Northwest Biotherapeutics, Inc.
PR Newswire - Wed Sep 23, 5:08PM CDT
Rigrodsky & Long, P.A.:
NWBO: 4.88 (+0.01)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Northwest Biotherapeutics, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NWBO
GlobeNewswire - Wed Sep 23, 2:31PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of Northwest Biotherapeutics, Inc. (Nasdaq:NWBO) ("Northwest Biotherapeutics" or the "Company"
securities during the period between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until October 26, 2015 to seek appointment as lead plaintiff. NWBO: 4.88 (+0.01)
Global Cancer Vaccine Market & Clinical Trial Insight
M2 - Wed Sep 23, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n828vw/global_cancer) has announced the addition of the "Global Cancer Vaccine Market & Clinical Trial Insight" report to their offering. The attractiveness for cancer vaccines has increased in past few years due to their characteristic properties like less side effects, low toxicity and high specificity. Besides, innovations related to novel delivery methods have also made them a lucrative option. Unlike traditional methods, they can be used for targeting the sub-group of cancers without effecting normal cells. Another factor in their favor is their high efficacy levels as compared to the presently available cancer therapeutics. The market size of cancer vaccines category is many fold smaller than other cancer therapeutics categories. Due to nascent stages of industry-life cycle and late introduction in market has decreased their overall share. To tap this cancer market category, many global companies are actively investing in cancer vaccine development. The market penetration is expected to increase with the competition among various pharmaceutical companies to get a larger portion of this market category. The cancer vaccines have to go through a long journey before enjoying the status of blockbuster drug. Presently, they have achieved a lot of success in both therapeutic and preventive field. However, inclination of market and researchers seems to be more towards the preventive category of cancer vaccines. For therapeutic side, it should be noted that novel methods for cancer eradication has been made. The future of cancer vaccines looks optimistic and plenty of cancer vaccines will hit the shelf in coming years. Key Topics Covered - Global Cancer Market Overview - Emergence of Personalized Cancer Vaccines - Platforms for Cancer Vaccines Delivery - Mechanism of Cancer Vaccines - Global Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country - Global Cancer Vaccine Clinical Pipeline: 298 Vaccines - Marketed Cancer Vaccines: 15 Vaccines - Regulatory Framework for Cancer Vaccines Development & Marketing Companies Mentioned - AVAX Technologies - Advaxis - Celldex Therapeutics - Dendreon Corporation - Galena Biopharma - GlaxoSmithKline - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - KAEL-GemVax - Liponova - MedImmune - Merck - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Novartis - Peregrine Pharmaceuticals - Recombio - Roche - Sanofi - Seattle Genetics - Valeant Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/n8...bal_cancer.
INO: 6.33 (-0.13), NWBO: 4.88 (+0.01), MRK: 54.66 (-0.21), CLDX: 12.06 (-0.22), NLNK: 38.27 (+0.89), GALE: 1.68 (-0.05), GSK: 43.06 (+0.27), IMUC: 0.39 (-0.01), NVS: 90.43 (-0.53)
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Northwest Biotherapeutics, Inc.
PR Newswire - Fri Sep 18, 6:45PM CDT
Ryan & Maniskas, LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of persons who purchased or acquired the shares of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NASDAQ: NWBO) between March 8, 2013 and August 20, 2015, inclusive (the "Class Period" . NWBO: 4.88 (+0.01)
Northwest Bio CEO: Brain Tumor Vaccine Study Still Suspended
at The Street - Wed Sep 16, 1:24PM CDT
Slightly more than 300 out of a required 348 brain tumor patients are currently enrolled in Northwest Bio's DCVax-L phase III study.
NWBO: 4.88 (+0.01)
NW Bio Presenting New DCVax-Direct Poster At "The Inaugural International Cancer Immunotherapy Conference: Translating Science Into Survival" In New York City On Wednesday, September 16, 2015
PR Newswire - Wed Sep 16, 8:20AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Chief Technical Officer, Dr. Marnix Bosch, will present a new DCVax-Direct poster at the Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival 2015. The Conference is being held at the Sheraton New York Times Square Hotel from September 16th to 19th, 2015. NWBO: 4.88 (+0.01)
Deadline in Lawsuit for Investors in Northwest Biotherapeutics, Inc (NASDAQ:NWBO) Shares Announced by Shareholders Foundation
GlobeNewswire - Tue Sep 15, 9:40AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit was filed in Maryland on behalf of certain purchasers of shares of Northwest Biotherapeutics, Inc (NASDAQ:NWBO) over alleged Securities Laws Violations by Northwest Biotherapeutics, Inc.
NWBO: 4.88 (+0.01)
NW to Present at 4th Annual SMi Cancer Vaccines Conference in London On Wednesday, September 16, 2015
PR Newswire - Mon Sep 14, 8:51AM CDT
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that CEO Linda Powers will present at the SMi 4th Annual Cancer Vaccines Conference in London on Wednesday, September 16, 2015 at the Marriott Hotel, Regents Park. NWBO: 4.88 (+0.01)
